Research & Projects

ESCMID Panorama

Abstract Topics

2 Drug Discovery

23. Shotgun metagenomic and functional metagenomic approach for unraveling of 

antimicrobial potential of microbial communities from Western Balkans glacial lakes sediments

25. Analysis of Escherichia coli essential genes in 63 strains complete genomes, a search of new therapeutic alternatives.

28. Receptor specificity and mode of action of SAHKI, an inhibitor of two component histidine kinase to attenuate infections caused by multiple drug resistant Staphylococcus aureus

30. Phagemid-based expression of synthetic sRNA to silence shiga toxins; a strategy towards RNA-based therapeutics 

36. Genome wide profiling of Mycobacterium Tuberculosis exposed to novel anti-tuberculosis agent, thienothiazole carboxamide (TTCA) derivatives. 

37. Structure-activity relationships of TTCA series for identification of novel anti-tubercular agents 

38. Antibacterial and Synergistic Activity of Δ9-tetrahydrocannabinol.

39. In Quest of A Novel Scaffold To Combat MDR/XDR Tuberculosis

42. Miniaturization of whole-cell bacterial bioreporter assay to identify quorum-sensing interference activity of chemical compounds

43. In vitro Characterization of Novel P. aeruginosa Quorum Sensing Inhibitors identified by In Silico Screening

44. Targeting Quorum sensing: Discovery of LsrK inhibitors

53. Next-generation antimicrobials based on CRISPR-Cas3 enhanced bacteriophages.

55. High Density Transposon Mutant Profiling Enables the Discovery and Development of Novel Antimicrobials

59. Evaluating bacterial thermoregulation mechanisms as an alternative drug target

61. Modulation of Quorum Sensing in a Gram-Positive Pathogen by Linear Molecularly
Imprinted Polymers with Anti-infective Properties.

62. Investigation of Narrow Spectrum Targets in Antibacterial Drug Discovery

70. Carbonyl Cyanide m-Chlorophenylhydrazone (CCCP) and no Other Efflux Pump Inhibitor
Reversed Resistance to Polymyxins in Enterobacteriaceae Isolated from Bloodstream Infections

74. A New Endolysin from Acinetobater baumannii Ab105Ф1 bacteriophage with
Gram-negative antimicrobial activity

75. Antimicrobial activity from mutant lytic phage obtained from the Ab105-2ϕ
prophage harbouring clinical strain of Acinetobacter baumannii.

91. Screening and Synergy Study Applications for New Antibacterial Compounds
against ESKAPE bacteria

Contact details: Riccardo Russo  (Newark, NJ, USA):

97. New tricks for old drugs – Uncovering the mechanism of action of thioridazine in
Salmonella Typhimurium

98. Repurposing zinc and cobalt organometallic compounds as effective antimicrobials
against Gram-positive and -negative bacteria

112. A polypharmacological approach to address antibacterial resistance: inhibition of Histidine Kinases by targeting the ATP binding domain. 

114. Understanding the Bacterial Permeation of Drug-Like Molecules

130. Identification of drug and vaccine candidates based on functional annotation of
hypothetical proteins in Neisseria gonorrhoeae.

134. Small-molecule anti-virulence agents F12 and F19 against Gram-positive pathogens

135. Synthesis and Evaluation of Novel Bacterial Topoisomerase Inhibitors with
Reduced hERG Inhibition

137. Repurposing of a non-antimicrobial drug to treat bacterial infections caused
by Gram-negative pathogens

142. Identification of potential narrow-spectrum antibiotics for the treatment of bacterial enteric infections through a phenotypic screening in Shigella flexneri

147. Discovery of FtsZ and FtsA Inhibitors 

148. Prediction of Novel Antimicrobials using Large Screening Data

L5. Antibiofilm activity of ocellatin peptides against multidrug-resistant Pseudomonas aeruginosa


3 Drug Development

15. Towards new β-lactamase inhibitors: chemistry and modeling driven approach

17. Octapeptins: New Lipopeptides for XDR Gram-Negative Infections

18. Glycopeptide derivatives with potent activity against multi-drug resistant
pathogenic bacteria

31. BARDA’s Model to Support Antibiotic Development

33. Getting drug into Gram negative bacteria: exploiting the porins pathway

35. Potential antimicrobials fighting XDR-pathogens; A study on the isolation and characterization of lytic bacteriophages effective on colistin resistance K. pneumoniae

46. Spectrum of Activity of RX-P2382, a Novel Class of Bacterial Ribosome Inhibitor 

49. The Safety of Iclaprim among Diabetic Patients for the Treatment of Acute Bacterial
Skin and Skin Structure Infections (ABSSSI): Pooled REVIVE Studies 

50. Surveillance of Iclaprim Activity: In Vitro Susceptibility of Drug-Susceptible and
-Resistant Beta-hemolytic Streptococci Collected During 2012-2016
from Skin and Skin Structure Infections

51. In vitro activities of omadacycline against rapidly growing mycobacteria 

52. Iclaprim Activity Against Clinical Isolates Causing Acute Bacterial Skin and Skin
Structure Infections (ABSSSI) in the Phase 3 REVIVE-1 and REVIVE-2 Studies

54. Building a European Laboratory Network for Anti-infective Clinical Trials –
COMBACTE LAB-Net: 5 Years in

56. SMT-571: The Development of a Novel Oral Antibiotic to Treat Multi-Drug Resistant Neisseria gonorrhoeae

57. Characterization of novel cyclic polypeptides with potent in vitro and in vivo activity against multidrug-resistant Gram-negative pathogens, and with reduced nephrotoxicity relative to colistin

58. Pharmacokinetics and Efficacy of Ceftolozane/Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbit Model

60. Surveillance of Iclaprim Activity: In Vitro Susceptibility of Gram-Positive Skin and Skin
Structure Pathogens Collected During 2004-2016

63. A phase 3, randomized, double-blind, multi-center study to compare the safety and efficacy
of IV to oral omadacycline to moxifloxacin for the treatment of adult patients with
CABP (The OPTIC Study)

64. A phase 3 randomized, double-blind, multi-center study to compare the safety and efficacy
of oral omadacycline to oral linezolid for treating adult subjects with ABSSSI (OASIS-2 study)

68. Outer membrane protein targeting antibiotics (OMPTAs): In vitro and in vivo characterization of a novel class of compound

72. Project Pillar Phase II: Provision of Clinical Strains

80. In Vitro Activity Evaluation of a Next-Generation Polymyxin, SPR206, against
Non-Fermentative Gram-Negative Bacilli Responsible for Human Infections

81. Activity of Investigational Polymyxin-B-like Compound (SPR206) Against Set of
Enterobacteriaceae Organisms Responsible for Human Infections

84. Assessment of AUC-Based Therapeutic Drug Management (TDM) Algorithms for Plazomicin Therapy in Patients with Bloodstream Infection (BSI)

85. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses to Support Plazomicin Dose Selection and Recommendations for Interpretive Criteria for In Vitro Susceptibility Testing for Enterobacteriaceae 

86. Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2 and 3 Studies

87. Targeting polymyxin- and carbapenem-resistant Klebsiella pneumoniae (KPC-KP) via a novel, integrated mechanistic approach

88. Comprehensive Penicillin-Binding Protein (PBP) Occupancy Patterns of 18 Drugs in Acinetobacter baumannii

93. A panel of MDR P. aeruginosa clinical isolates for pharmacology studies with murine lung and thigh infection models 

95. Lead Development of PolC Polymerase Inhibitors against Resistant Gram-positive Pathogens

96. Activity of Antimicrobial peptides against Mycobacterium abscessus

99. Lysin CF-301 (Exebacase) Resensitizes Methicillin-Resistant Staphylococcus aureus (MRSA) to Penicillin Derivatives and First Generation Cephalosporins 

100. Pharmacokinetics-Pharmacodynamics (PK-PD) of Plazomicin (PLZ) against
Carbapenem-Resistant Enterobacteriaceae (CRE) in Neutropenic Murine Thigh
Infection and Pneumonia Models

101. Method for Generating a Pharmacokinetic/Pharmacodynamic (PK/PD) Breakpoint
from Murine Infection Studies with Multiple Strains.

103. A novel approach to decrease efflux-mediated drug resistance in Neisseria gonorrhoeae

104. High-dose Nitric Oxide inhibits growth of Mycobacterium Abscessus

107. The Role of Whole Genome Sequencing on Post-Marketing Surveillance Programs:
Results of the INFORM Surveillance Program for Ceftazidime-Avibactam in the United States

110. Evaluation of Proline-rich antimicrobial Peptides for Treatment of Ventilator-Associated Pneumoniae

111. Tedizolid In Vitro Activity against a Contemporary Challenge Collection of
Multidrug-Resistant Enterococcal Clinical Isolates

113. Novel inhibitors of leucyl-tRNA synthetase

116. Analysis of Oritavancin In vitro Activity against Enterococcal Isolates and Resistant Subsets

122. Nano-mupirocin for the treatment of resistant gonorrhea

131. Population Pharmacokinetic Analyses for Arbekacin After Administration of ME1100 Inhalation Solution

136. Importance of Utilizing Local Carbapenem-Resistant Enterobacteriaceae (CRE)
Surveillance Isolates to Determine Potential Efficacy of Novel Agents:
Meropenem/Vaborbactam (M/V) Exhibits Robust Activity at a US Healthcare Center
with a Predominance of Non-KPC-Producing CRE

138. In Vivo Efficacy of SPR206 in an Immunocompetent Murine Ascending UTI Infection Model Caused by Escherichia coli  

139. in Murine Lung and Thigh Infection Models Caused by Multi-Drug Resistant Pathogens Pseudomonas aeruginosa and Acinetobacter baumannii

145. Understanding the SAR Interplay for Kidney Exposure and Cytotoxicity Facilitates the Design of Improved Polymyxin Derivatives – Identification of SPR206 as a Development Candidate

146. A GLP 14-Day Repeat Dose Toxicology Study of SPR206 in Monkeys  

149. A Hollow-Fiber Infection Model  to Evaluate the Prevention of On-Therapy Resistance of Neisseria gonorrhoeae to Gepotidacin

L1. Proteomics Analysis of Proteins Associated with Urinary Tract Infections

L2. Pharmacokinetics and Pharmacodynamics of Tebipenem (SPR859) for Multidrug Resistant
Enterobacteriaceae in a Hollow Fibre Infection Model

L3. Pharmacokinetics and Pharmacodynamics of SPR994 for Multidrug Resistant



4 Epidemiology


12. Molecilar epidemiology and drug susceptibility of Pseudomonas aeruginosa in a tertiary
care centre in Kosovo

16. Antibiogram of Gram-negative human pathogens isolated in India. 

22. Multiple-Antibiotic Resistance and presence of CTX-M genes among Enterobacteriaceae isolates from different sources in Iwo, Osun State, Nigeria.

32. Drug resistant pattern of bacterial isolates in infected wounds at Bahir Dar Regional health research laboratory center, Northwest Ethiopia

34. Antimicrobial resistance, genomic and molecular epidemiologic analysis of Salmonella serovars in Hacettepe University Hospitals


48. A survey on multidrug resistance and virulence genes in Pseudomonas aeruginosa isolates in a major hospital in Shiraz, Iran

69. Study Of Extended Spectrum B-Lactamase Producing Enterobacteriacae From healthcare workers From Different Hospitals In Khartoum State 2016-2017

76. Isolation and Characterization of NDM-1 Producing Klebsiella Pneumoniae from three Palestinian Hospitals  

90. Species diversity of IMP-producing Acinetobacter isolated from patients in pediatric and neonatal intensive care units: clinical features, diagnosis and treatment.

92. Clavulante stability in widely used child-appropriate formulations is unlikely to be adequate
for use in treating young children in Asia

123. Detection of CPE in rectal swaps using four different phenotypic techniques and Check-Direct CPE multiplex PCR, using PCR and sequencing as a reference methods.

124. Carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa bacteremia in Southern Veterans Hospital 

127. Ciprofloxacin-Resistant Salmonella enterica serovar Typhi infections in Travelers returning from India, Republic of Korea

128. Genetic relationships among Fluoroquinolone-resistant Shigella sonnei isolates from humans in Republic of Korea, 2008-2016

129. Comparative analysis of extended-spectrum β-lactamase (ESBL) CTX-M-15-producing Salmonella enterica serovar Enteritidis isolates from human and chicken in Republic of Korea.

132. Complete genome sequence of a blaKPC-2-positive Klebsiella pneumoniae strain isolated from the effluent of an urban sewage treatment plant in Japan

140. Current oral (PO) regimen options are suboptimal for hospitalized patients with urinary tract infections (UTI) due to contemporary resistant Enterobacteriaceae (ENT): A multicenter analysis

141. The impact of antibiotic resistance on hospitalized patients with Enterobacteriaceae (ENT) urinary tract infections (UTI): A multicenter analysis

L6. Diabetic foot ulcers: the challenges of multidrug resistance and the possibilities
interspecies competition may offer

6 Mx of Resistance

9. Study of ompk35 and ompk36 Expression in Carbapenem Resistant ESBL Producing Clinical
Isolates of Klebsiella Pneumoniae

19. Effect of amoxicillin metabolites on the induction of resistance to amoxicillin susceptible
bacterial strains.

66. Effect of Efflux Pump Inhibitors to Efficacy of Meropenem on Acinetobacter spp. Clinical Isolates

67. Investigating the Effect of Phenylalanine-arginine-beta-naphthylamide to Minimum Inhibition Concentration of Ciprofloxacin and Expression of Efflux Pump Genes in Acinetobacter baumannii Clinical Isolates 

77.  Improve Awareness and Understanding Antibiotics Resistant Through Participation in Public Cultural Forums

83. Optimizing Aminoglycoside Selection for KPC-Producing Klebsiella pneumoniae with Aminoglycoside Modifying Enzyme AAC(6’)-Ib

120.  Evaluation and interpretation of antimicrobial resistance in patient's Rifampicin- or Multidrug-Resistant Tuberculosis by Northern Iran: An analysis of past 10 years

133. Growth Inhibition of Streptococcaceae in Healthy Gut Flora by Interocin of Streptococcus intermedius TYG1620 Isolated from a Human Brain Abscess

7 Plants


8. Antibacterial Potentials of the Leaf Extracts of Siam Weed (Chromolaena odorata) on Wound Isolates

13. Innate Defense Regulators (IDRs) – Agnostic Therapy to Treat Bacterial Infections and Fight Resistance.

40. Growth and biofilm formation inhibition activity against carbapenem resistant
Acinetobacter baumannii is obtained reproducibly from 7 different water extracts
of complex mixes of edible plants

89. Antibacterial and antioxidant activity of ethanolic extracts of Uvaria chamae roots on Bacteria Multiresistance: Involvement of chalcones and dihydrochalcones

105. Valuation of some plants of the traditional Beninese pharmacopoeia used in the control of pathogenic enterobacteria

108. Antimicrobial Activities of Thymus vulgaris and Cymbopogon citratus on